RxDoctor Payments Data

Sadia Khan, MD

Internal Medicine · Saginaw, MINPI 1881633048

Payments from drug & device makers

$4,068in general payments, 2019–2025

Across 168 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$529
  • Otsuka America Pharmaceutical, Inc.$477
  • Johnson & Johnson$322
  • Novo Nordisk$297
  • Axsome Therapeutics, Inc.$279
  • Lilly USA, LLC$206
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,068100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,068 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$72,775
Medicare patients
395
Services billed
1,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$59,480
JardianceEmpagliflozin33$12,292
LokelmaSodium Zirconium Cyclosilicate27$10,814
XareltoRivaroxaban35$10,281
EntrestoSacubitril/Valsartan32$9,719
Incruse ElliptaUmeclidinium Bromide21$8,072
Levothyroxine Sodium237$7,974
LantusInsulin Glargine,hum.Rec.Anlog79$6,090
LevemirInsulin Detemir49$5,802
Atorvastatin Calcium354$3,405
ProcritEpoetin Alfa18$3,088
NovologInsulin Aspart32$3,068
Bethanechol Chloride79$2,671
Lacosamide13$2,509
RetacritEpoetin Alfa-Epbx16$2,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Procrit$322$13,36953 claims
Boehringer IngelheimJardiance$109$12,29233 claims
AstraZenecaLokelma$529$10,81427 claims
NovartisEntresto$67$9,71932 claims
Novo NordiskLevemir, Novolog$297$8,87181 claims
GSKIncruse Ellipta$17$8,07221 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$7,974237 claims
Sanofi-aventis U.S. LLCLantus$15$6,09079 claims
Lilly USA, LLCHumalog$206$2,05727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →